返回 Agenda
Session 2: An In-Depth Look at ISPY2
Session Chair(s)
Scott Berry, PHD
President and Senior Statistical Scientist
Berry Consultants LLC, United States
Daniel Millar, MBA
Senior Director, Strategic Business Transformation
Johnson & Johnson, United States
Get and in-depth look at ISPY2, an exploratory-phase platform trial designed to investigate new treatments for biomarker-identified subtypes of early-stage breast cancer in the context of neoadjuvant therapy.
Speaker(s)
An In-Depth Look at I-SPY 2
Donald A Berry, PHD
M.D. Anderson Cancer Center, United States
Professor, Department of Biostatistics